Publications
349
Citations
9,351
Est. group size
—
Recurring co-author estimate
Active years
50
Publishing since 1977
Timothy F. Burns works on lung cancer, focusing on genetic drivers such as EGFR, KRAS, and MET mutations and how tumors develop drug resistance. His work spans laboratory studies of cancer cell biology and clinical trials testing new targeted therapies and drug combinations in non-small cell lung cancer patients, including those with brain metastases.
Publication output was steady at around 10-19 per year from 2017-2022, then sharply increased starting in 2023, suggesting a recent surge in research and clinical trial activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract 1311: Feasibility of plasma ctDNA for detecting brain metastasis-specific alterations in lung cancer.
Cancer Research · 2026
- Abstract 7039: FER drives drug-tolerant persister cell survival in EGFR-mutant lung cancer.
Cancer Research · 2026
- SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLC
Future Oncology · 2026
- Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
Journal of Clinical Oncology · 2025
- Advances in the treatment of <i>KRAS</i><sup><i>G12C</i></sup> mutant non–small cell lung cancer
Cancer · 2025
- MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
Journal of Clinical Investigation · 2025
- Phase 1 clinical trial of the ataxia telangiectasia and Rad3‐related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)
Cancer · 2025
- Time-Resolved Crystallography Reveals the Mechanisms of GTP hydrolysis for N-RAS and the Oncogenic Mutants G12C, G12V and Q61L
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Supplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2025
- Supplemental Figure 5 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2025
- Supplemental Figure 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2025
- Supplemental Figure 3 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2025
- Supplemental Figure 4 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2025
- Supplemental Table 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2025
- Supplemental Methods 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i>-Mutant Non–Small Cell Lung Cancer
2025
- Journal of Clinical Oncology×29
- Cancer Research×18
- Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature×11
- Annals of Oncology×6
- Molecular Cancer Therapeutics×5
- Nobuyuki Yamamoto
Medicine · Indiana University
- Nasser H. Hanna
Medicine · Indiana University
- Gregory A. Otterson
Medicine · The Ohio State University
- Ai Ni
Medicine · The Ohio State University
- Tamio Okimoto
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile